|
|
| | 6-[4-(diethylamino)-3-nitrophenyl]-5-methyl-2,3,4,5-tetrahydropyridazin-3-one Basic information |
| | 6-[4-(diethylamino)-3-nitrophenyl]-5-methyl-2,3,4,5-tetrahydropyridazin-3-one Chemical Properties |
| density | 1.28±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO : 50 mg/mL (164.29 mM; Need ultrasonic) | | pka | 13.30±0.60(Predicted) | | form | Solid | | color | Orange to red |
| | 6-[4-(diethylamino)-3-nitrophenyl]-5-methyl-2,3,4,5-tetrahydropyridazin-3-one Usage And Synthesis |
| Uses | DNMDP, a phosphodiesterase 3A (PDE3A) inhibitor, is a potent and selective cancer cell cytotoxic agent. DNMDP binding to PDE3A promotes an interaction between PDE3A and Schlafen 12 (SLFN12). DNMDP shows clear cell-selective cytotoxicity[1]. | | Biological Activity | DNMDP, a phosphodiesterase 3A (PDE3A) inhibitor, is a potent and selective cancer cell cytotoxic agent. DNMDP binding to PDE3A promotes an interaction between PDE3A and Schlafen 12 (SLFN12). DNMDP shows clear cell-selective cytotoxicity[1].
DNMDP (0-1000 μM; 48 hours) shows clear cell-selective cytotoxicity[1]. HeLa cells undergo apoptosis upon DNMDP treatment, indicates by caspase activity detected by a caspase-sensitive luciferase assay and by poly ADP ribose polymerase (PARP) cleavage. At a concentration of 100 nM, DNMDP specifically inhibits both PDE3A and PDE3B, weakly inhibits PDE10, and had little or no detectable effect on other phosphodiesterases[1]. | | IC 50 | PDE3 | | References | [1]. de Waal L, et al. Identification of cancer-cytotoxic modulators of PDE3A by predictive chemogenomics. Nat Chem Biol. 2016 Feb;12(2):102-8. |
| | 6-[4-(diethylamino)-3-nitrophenyl]-5-methyl-2,3,4,5-tetrahydropyridazin-3-one Preparation Products And Raw materials |
|